These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 12783289)
1. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208 [TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851 [TBL] [Abstract][Full Text] [Related]
4. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227 [TBL] [Abstract][Full Text] [Related]
5. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Guay DR Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795 [TBL] [Abstract][Full Text] [Related]
7. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662 [TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Major PP; Coleman RE Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861 [TBL] [Abstract][Full Text] [Related]
10. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597 [TBL] [Abstract][Full Text] [Related]
11. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Body JJ; Louviaux I; Dumon JC Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689 [TBL] [Abstract][Full Text] [Related]
12. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Major P Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736 [TBL] [Abstract][Full Text] [Related]
13. [Pamidronate in the treatment of tumor-associated hypercalcemia]. Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492 [TBL] [Abstract][Full Text] [Related]
14. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
15. [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia]. Wang T; Song ST; Jiang ZF; Bian SG; Wang YJ; Li LQ; Zhu J Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):739-41. PubMed ID: 15733393 [TBL] [Abstract][Full Text] [Related]
17. Current management strategies for hypercalcemia. Pecherstorfer M; Brenner K; Zojer N Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562 [TBL] [Abstract][Full Text] [Related]
18. Ibandronate. Dooley M; Balfour JA Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134 [TBL] [Abstract][Full Text] [Related]
20. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Zojer N; Keck AV; Pecherstorfer M Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]